Source:http://linkedlifedata.com/resource/pubmed/id/16282291
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
2005-11-11
|
| pubmed:abstractText |
We assessed the prophylactic efficacy of azithromycin (250 mg/day) against malaria in 276 adults in western Thailand in a randomized, double-blind, placebo-controlled trial. After antimalarial suppressive treatment, volunteers were randomized in a 2:1 ratio to either the azithromycin or placebo, respectively. Study medication was given for an average of 74 days. The azithromycin group (n = 179) had five endpoint parasitemias (1 Plasmodium vivax and 4 P. falciparum), and the placebo group (n = 97) had 28 endpoint parasitemias (21 P. vivax, 5 P. falciparum, and 2 mixed infections). Adverse events and compliance and withdrawal rates were similar in both groups. The protective efficacy (PE) of azithromycin was 98% for P. vivax (95% confidence interval [CI] = 88-100%). There were too few cases to reliably estimate the efficacy of azithromycin for P. falciparum (PE =71%, 95% C =-14-94%). We conclude that daily azithromycin was safe, well-tolerated, and had a high efficacy for the prevention of P. vivax malaria.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
AIM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Nov
|
| pubmed:issn |
0002-9637
|
| pubmed:author |
pubmed-author:BrewerThomas GTG,
pubmed-author:ChuanakNiphonN,
pubmed-author:EamsilaChirapaC,
pubmed-author:HeppnerD GrayDGJr,
pubmed-author:KeepLisa WLW,
pubmed-author:KyleDennis EDE,
pubmed-author:LaoboonchaiAnintitaA,
pubmed-author:McDanielPhilipP,
pubmed-author:MillerRobert ERE,
pubmed-author:PermpanichBarnyenB,
pubmed-author:SooktoPrasitP,
pubmed-author:TangDouglas BDB,
pubmed-author:TulyayonSomchitS,
pubmed-author:UhlKathleenK,
pubmed-author:UthaimongkolNichapatN,
pubmed-author:WalshDouglas SDS,
pubmed-author:WimonwattrawateeTheeraT,
pubmed-author:WongsrichanalaiChansudaC,
pubmed-author:YongvanitchitKosolK
|
| pubmed:issnType |
Print
|
| pubmed:volume |
73
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
842-9
|
| pubmed:dateRevised |
2006-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:16282291-Adult,
pubmed-meshheading:16282291-Animals,
pubmed-meshheading:16282291-Antimalarials,
pubmed-meshheading:16282291-Azithromycin,
pubmed-meshheading:16282291-Chemoprevention,
pubmed-meshheading:16282291-Double-Blind Method,
pubmed-meshheading:16282291-Female,
pubmed-meshheading:16282291-Humans,
pubmed-meshheading:16282291-Malaria, Vivax,
pubmed-meshheading:16282291-Male,
pubmed-meshheading:16282291-Parasitemia,
pubmed-meshheading:16282291-Plasmodium vivax,
pubmed-meshheading:16282291-Thailand,
pubmed-meshheading:16282291-Treatment Outcome
|
| pubmed:year |
2005
|
| pubmed:articleTitle |
Randomized, controlled, double-blind trial of daily oral azithromycin in adults for the prophylaxis of Plasmodium vivax malaria in Western Thailand.
|
| pubmed:affiliation |
Department of Immunology and Medicine, United States Army Medical Component, Armed Forces Research Institute of Medical Sciences, Bangkok, Thailand. donald.heppner@na.amedd.army.mil
|
| pubmed:publicationType |
Journal Article,
Comparative Study,
Randomized Controlled Trial
|